NCT02688517 Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
| NCT ID | NCT02688517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Malignant Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,100 participants |
| Start Date | 2013-02 |
| Primary Completion | 2030-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,100 participants in total. It began in 2013-02 with a primary completion date of 2030-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.
Eligibility Criteria
Inclusion Criteria: * Karnofsky/Lansky performance score \>= 30 * A signed written informed consent * Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment * Paraffin blocks of the patient's tumor tissue are available and accessible for analysis Exclusion Criteria: * Karnofsky/Lansky performance score \< 30 * Life expectancy \< 3 months
Contact & Investigator
Clinical Trials Office
📞 732-235-2465
Shridar Ganesan
PRINCIPAL INVESTIGATOR
Rutgers Cancer Institute of New Jersey
Frequently Asked Questions
Who can join the NCT02688517 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02688517 currently recruiting?
Yes, NCT02688517 is actively recruiting participants. Visit ClinicalTrials.gov or contact Rutgers, The State University of New Jersey to inquire about joining.
Where is the NCT02688517 trial being conducted?
This trial is being conducted at Brick, United States, Holmdel, United States, Jersey City, United States, Manahawkin, United States and 7 additional locations.
Who is sponsoring the NCT02688517 clinical trial?
NCT02688517 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Shridar Ganesan at Rutgers Cancer Institute of New Jersey. The trial plans to enroll 1,100 participants.